Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark OfficePRNewsWire • 12/29/22
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual MeetingPRNewsWire • 11/07/22
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual MeetingPRNewsWire • 10/26/22
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System AtrophyPRNewsWire • 10/13/22
Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement DisordersPRNewsWire • 09/26/22
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System AtrophyPRNewsWire • 09/20/22
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in EuropePRNewsWire • 08/25/22
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System AtrophyPRNewsWire • 07/06/22
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in ItalyPRNewsWire • 06/23/22
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System AtrophyPRNewsWire • 06/02/22
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United KingdomPRNewsWire • 04/27/22
Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual MeetingPRNewsWire • 04/07/22
Alterity Therapeutics Highlights New Publications On ATH434 In Parkinson's DiseaseBenzinga • 01/28/22
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's DiseasePRNewsWire • 01/28/22
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer'sPRNewsWire • 01/06/22
Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual ConferencePRNewsWire • 01/05/22
Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical TrialPRNewsWire • 12/14/21
Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021PRNewsWire • 11/09/21
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative DiseasesPRNewsWire • 11/05/21